

Ahmet GÃ¼l

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1542236/publications.pdf>

Version: 2024-02-01

274
papers

14,919
citations

20817

60
h-index

19749

117
g-index

278
all docs

278
docs citations

278
times ranked

11694
citing authors

#	ARTICLE	IF	CITATIONS
1	Core Set of Domains for Outcome Measures in Behçet's Syndrome. <i>Arthritis Care and Research</i> , 2022, 74, 691-699.	3.4	21
2	Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. <i>Rheumatology International</i> , 2022, 42, 457-467.	3.0	4
3	IL-17A and IFN- γ are Up-regulated in CD4 and $\gamma\delta$ T Cells in Active Behcet's Disease Patients. <i>Immunology Letters</i> , 2022, 242, 37-45.	2.5	8
4	Psychometric validation of Barkley's Adult Sluggish Cognitive Tempo (SCT) Ratings Scale -Turkish version and distinguishing SCT from attention deficit-hyperactivity disorder (ADHD) among Turkish adults. <i>Research in Developmental Disabilities</i> , 2022, 121, 104155.	2.2	6
5	Description of damage in different clusters of patients with antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 433-442.	1.6	5
6	A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis. <i>Open Access Rheumatology: Research and Reviews</i> , 2022, Volume 14, 39-42.	1.6	2
7	Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine. <i>Journal of Medical Virology</i> , 2022, 94, 3431-3437.	5.0	4
8	The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 555-564.	1.6	1
9	Effect of different cytokines in combination with IL-15 on the expression of activating receptors in NK cells of patients with Behçet's disease. <i>Immunologic Research</i> , 2022, 70, 654-666.	2.9	4
10	An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1154-1163.	1.8	26
11	Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 466-474.	2.1	6
12	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. <i>Rheumatology</i> , 2021, 60, 3799-3808.	1.9	29
13	Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. <i>Rheumatology International</i> , 2021, 41, 439-448.	3.0	2
14	mRNA Expression Levels of NKp30, NKp46, NKG2D, Perforin and Granzyme in the Behçet's Disease. <i>Turkish Journal of Immunology</i> , 2021, , .	0.1	0
15	A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. <i>Rheumatology International</i> , 2021, 41, 1667-1672.	3.0	2
16	The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response. <i>International Journal of Infectious Diseases</i> , 2021, 105, 756-762.	3.3	16
17	POS0142â€¦MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ASSOCIATED FACTORS: REAL LIFE DATA FROM A SINGLE CENTER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 282.3-283.	0.9	0
18	AB0766â€¦SUCCESSFUL TEATMENT OF ANKYLOSING SPONDILITIS ASSOCIATED AA AMYLOIDOSIS WITH SECUKINUMAB: A CASE SERIES WITH THREE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1409.3-1410.	0.9	1

#	ARTICLE	IF	CITATIONS
19	AB0448â€¦SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: PREDOMINANCE OF PULMONARY FIBROSIS AS A RISK FACTOR FOR MORTALITY IN A SINGLE CENTER COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1251.2-1252.	0.9	0
20	POS1339â€¦MORE FREQUENT AND EARLIER HIP INVOLVEMENT IN SPONDYLOARTHRITIS ASSOCIATED WITH FAMILIAL MEDITERRANEAN FEVER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 951.3-952.	0.9	0
21	AB0653â€¦COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1359.1-1359.	0.9	0
22	POS0706â€¦PERFORMANCES OF DIFFERENT CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN A SINGLE CENTER COHORT FROM TURKEY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 602.1-603.	0.9	0
23	POS0766â€¦CLUSTER ANALYSIS AND COMPARISON OF CUMULATIVE DAMAGE BY DIAPS IN A SINGLE CENTER COHORT OF APS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 636.2-637.	0.9	0
24	POS1259â€¦FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 913.2-914.	0.9	0
25	POS1445â€¦RETINOL BINDING PROTEIN 4 AS AN ACUTE PHASE REACTANT AND BIOMARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AMYLOIDOSIS COMPARED TO INFECTIONS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1006.2-1007.	0.9	0
26	AB0331â€¦PULMONARY INVOLVEMENT IN A SINGLE CENTER COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1191.1-1191.	0.9	0
27	POS0710â€¦ANALYSIS OF 5-YEAR HOSPITALIZATION DATA OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DAMAGE IS A RISK FACTOR FOR FREQUENT AND LONGER STAYS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 604.2-605.	0.9	0
28	OPO313â€¦PRELIMINARY CRITERIA FOR MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH CORONAVIRUS DISEASE-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 191.1-192.	0.9	0
29	AB0369â€¦EVALUATION OF BASELINE POSITRON EMISSION TOMOGRAPHY IN THE DIAGNOSIS AND ASSESSMENT OF GIANT CELL ARTERITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1210.2-1211.	0.9	0
30	POS1257â€¦HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 912-913.	0.9	3
31	Reinfection with SARSâ€CoVâ€2 in a kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2021, 23, e13695.	1.7	2
32	Inflammatory status might direct ILC and NK cells to IL-17 expressing ILC3 and NK subsets in Behcet's disease. <i>Immunology Letters</i> , 2021, 235, 1-8.	2.5	8
33	Buddâ€Chiari syndrome in Behçetâ€™s disease: a retrospective multicenter study. <i>Clinical Rheumatology</i> , 2021, , 1.	2.2	7
34	A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 2243-2247.	0.9	3
35	Initial complete blood count score and predicting disease progression in COVID-19 patients. <i>American Journal of Blood Research</i> , 2021, 11, 77-83.	0.6	0
36	Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center. <i>Ulusal Romatoloji Dergisi</i> , 2021, 13, 116-120.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Clinical characteristics of female patients with axial spondyloarthritis treated with tumor necrosis factor-alpha inhibitors and disease related outcomes after therapy. <i>Ulusal Romatoloji Dergisi</i> , 2021, 13, 100-106.	0.0	0
38	Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review. <i>Rheumatology International</i> , 2020, 40, 1903-1910.	3.0	19
39	Molecular dynamics simulations provide molecular insights into the role of HLA-B*51 in Behçet's disease pathogenesis. <i>Chemical Biology and Drug Design</i> , 2020, 96, 644-658.	3.2	8
40	P26â€¦Serum BAFF and APRIL as candidate biomarkers in systemic lupus erythematosus (SLE): a prospective follow-up study. , 2020, , .		0
41	P69â€¦Risk factors for adverse pregnancy outcome in patients with SLE. , 2020, , .		0
42	P73â€¦The relationship between pregnancy, disease activity and adverse pregnancy outcomes in systemic lupus erythematosus. , 2020, , .		0
43	P181â€¦Comparison of SLEDAI-2K and SLEDAI-2KG (glucocorticoid) indexes in patients with systemic lupus erythematosus (SLE). , 2020, , .		0
44	P9â€¦Validation of the adjusted global antiphospholipid syndrome score and correlation with extra-criteria manifestations. , 2020, , .		0
45	Letter: is pneumococcal vaccination safe during the COVID-19 pandemic?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 919-920.	3.7	2
46	COVID-19 is a Real Headache!. <i>Headache</i> , 2020, 60, 1415-1421.	3.9	204
47	Common genetic susceptibility loci link PFAPA syndrome, Behçet's disease, and recurrent aphthous stomatitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14405-14411.	7.1	52
48	Ancient familial Mediterranean fever mutations in human pyrin and resistance to <i>Yersinia pestis</i> . <i>Nature Immunology</i> , 2020, 21, 857-867.	14.5	90
49	The efficacy of anti-IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102332.	2.0	11
50	Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 379-388.	1.6	11
51	Genetics of Behçet's Disease. , 2020, , 223-233.		0
52	AB0485â€¦INVESTIGATION OF PERMANENT ORGAN DAMAGE IN GIANT CELL ARTERITIS: DISEASE FLARES ARE ASSOCIATED WITH INCREASED DAMAGE SCORES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1540.2-1540.	0.9	0
53	SAT0178â€¦HYDROXYCHLOROQUINE CONTROLS DISEASE ACTIVITY IN SLE AND MULTIMODAL IMAGING TECHNIQUES SHOULD BE USED TO DETECT OCULAR TOXICITY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1030.2-1031.	0.9	0
54	AB0486â€¦ANALYSIS OF 89 PATIENTS WITH GIANT CELL ARTERITIS FROM TURKEY: PET-CT AS AN EMERGING METHOD FOR DIAGNOSIS AND HIGH FLARE RATE WITH STANDARD CARE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1540.1-1541.	0.9	0

#	ARTICLE	IF	CITATIONS
55	AB0480â€¦AN OPEN-LABEL, EXPLORATORY STUDY TO ESTABLISH THE EFFICACY AND SAFETY OF 1-YEAR CANAKINUMAB TREATMENT IN BEHÄŒETÄ€™S DISEASE PATIENTS WITH NEUROLOGIC OR VASCULAR INVOLVEMENT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1537.3-1538.	0.9	0
56	FR10160â€¦THE CORRELATION BETWEEN PREGNANCY, DISEASE ACTIVITY AND ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 664.1-664.	0.9	0
57	SAT0261â€¦FEATURES AND RISK FACTORS OF SERIOUS INFECTIONS IN ANCA ASSOCIATED VASCULITIS: LONG TERM FOLLOW UP OF 186 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1073.1-1073.	0.9	0
58	THU0369â€¦EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 416.1-417.	0.9	0
59	SAT0200â€¦RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1042.1-1042.	0.9	0
60	SAT0346â€¦THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE ASSESSED BY ACTIVITY SCORES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1119.2-1119.	0.9	0
61	SAT0238â€¦VALIDATION OF THE ADJUSTED GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE AND CORRELATION WITH EXTRA-CRITERIA MANIFESTATIONS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1062.2-1062.	0.9	0
62	OP0274â€¦CLINICAL ASPECTS, LABORATORY CHARACTERISTICS AND TREATMENT RESPONSES OF AA AMYLOIDOSIS: SINGLE CENTER EXPERIENCE WITH 163 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 171.1-171.	0.9	0
63	THU0349â€¦THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 406.2-406.	0.9	0
64	AB0461â€¦ANCA-ASSOCIATED VASCULITIS: CLINICAL FEATURES, RELAPSE, ORGAN DAMAGE AND SURVIVAL IN 197 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1529.1-1529.	0.9	0
65	Cardiovascular risk in antiphospholipid syndrome: A comparison of thrombotic and obstetric disease subsets. <i>Ulusal Romatoloji Dergisi</i> , 2020, 12, 83-87.	0.0	0
66	Management of skin, mucosa and joint involvement of BehÄŒetÄ€™s syndrome: A systematic review for update of the EULAR recommendations for the management of BehÄŒetÄ€™s syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 752-762.	3.4	56
67	Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival. <i>Lupus</i> , 2019, 28, 1480-1487.	1.6	8
68	Classification criteria for autoinflammatory recurrent fevers. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1025-1032.	0.9	300
69	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1198-1201.	2.0	24
70	Clinical course of abdominal aortic aneurysms in BehÄŒet disease: a retrospective analysis. <i>Rheumatology International</i> , 2019, 39, 1061-1067.	3.0	9
71	BehÄŒet Disease. , 2019, , 647-665.		3
72	AB0524â€¦SERUM BAFF AND APRIL AS CANDIDATE BIOMARKERS IN SYSTEMÄ°C LUPUS ERYTHEMATOSUS (SLE): A PROSPECTIVE FOLLOW-UP STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	THU0303â€¦THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHÃ§ETâ€™S SYNDROME. , 2019, , .		2
74	281â€¦Lupus nephritis biomarkers. , 2019, , .		0
75	SAT0184â€¦.ASSOCIATION OF SERUM AND URINE LEVELS OF TWEAK, MCP-1 AND NGAL WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
76	Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With BehÃ§et Disease Uveitis. , 2019, 60, 52.		29
77	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
78	Improvement of Libman-Sacks endocarditis after combination of warfarin and immunosuppressive therapy. Turk Kardiyoloji Dernegi Arsivi, 2019, 47, 687-690.	0.5	4
79	Pseudodominance of autoinflammatory disease in a single Turkish family explained by co-inheritance of haploinsufficiency of A20 and familial Mediterranean fever. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 89-92.	0.8	3
80	Phenotypic variability including BehÃ§et's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A>G splice site mutation. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 142-146.	0.8	7
81	<i>IL1RN</i> Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€“1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	5.6	40
82	2018 update of the EULAR recommendations for the management of BehÃ§etâ€™s syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213225.	0.9	442
83	Use of Gevokizumab in Patients with BehÃ§etâ€™s Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocular Immunology and Inflammation, 2018, 26, 1023-1033.	1.8	82
84	A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-âˆšB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735.	0.9	176
85	Binding stability of peptides on major histocompatibility complex class I proteins: role of entropy and dynamics. Physical Biology, 2018, 15, 026005.	1.8	2
86	The association between P selectin glycoprotein ligand 1 gene variable number of tandem repeats polymorphism and risk of thrombosis in BehÃ§et's disease. International Journal of Rheumatic Diseases, 2018, 21, 2175-2179.	1.9	0
87	Dynamics of Inflammatory Response in Autoinflammatory Disorders: Autonomous and Hyperinflammatory States. Frontiers in Immunology, 2018, 9, 2422.	4.8	19
88	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
89	BehÃ§et Disease. , 2018, , 365-370.		0
90	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Annals of the Rheumatic Diseases, 2018, 77, 1558-1565.	0.9	114

#	ARTICLE	IF	CITATIONS
91	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018, 57, 2200-2212.	1.9	89
92	Molecular Diagnosis Experience in Familial Mediterranean Fever: The Most Frequent Mutations in the MEFV Gene. <i>Haseki Tip Bulteni</i> , 2018, 56, 42-49.	0.3	1
93	FRIO441â€¦Idiopathic inflammatory myopathies: clinical characteristics, survival and poor prognostic factors of 110 patients from turkey. , 2018, , .		0
94	FRIO675â€¦Rabiopred, an innovative theranostic tool to assist clinicians select an optimal anti-tnf alpha biological therapy for rheumatoid arthritis patients. , 2018, , .		1
95	SAT0489â€¦Assesment of persistent organ damage according to imacs (INTERNATIONAL MYOSITIS) Tj ETQq1 1 0.784314 rgBT /Ove... myositis. , 2018, , .		0
96	SAT0597â€¦New autoinflammatory phenotype manifesting as hypocomplementemic urticarial vasculitis and associated with homozygous agbl3 variant. , 2018, , .		0
97	Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 62-70.	1.8	52
98	Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. <i>Nature Genetics</i> , 2017, 49, 438-443.	21.4	129
99	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1750-1753.	2.0	25
100	Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. <i>Journal of Rheumatology</i> , 2017, 44, 619-625.	2.0	41
101	Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 115-120.	3.4	108
102	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 942-947.	0.9	175
103	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 906-913.	0.9	123
104	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology</i> , 2017, 56, 2102-2108.	1.9	84
105	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1933-1937.	2.0	33
106	Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. <i>Immunity</i> , 2017, 47, 183-198.e6.	14.3	245
107	THU0195â€¦Consistent efficacy and safety of tofacitinib in rheumatoid arthritis patients with inadequate response or intolerance to NON-MTX csdmards. , 2017, , .		1
108	Behçet's disease (or syndrome) â€œAn update. <i>Revue De Medecine Interne</i> , 2017, 38, A8-A9.	1.0	0

#	ARTICLE	IF	CITATIONS
109	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. <i>Arthritis Care and Research</i> , 2017, 69, 578-586.	3.4	75
110	OP0063-Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40. , 2017, , .		0
111	THU0329-Budd-chiari syndrome in Behçet's disease: a retrospective multicenter study. , 2017, , .		0
112	Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 77-82.	0.8	7
113	Reply to: Behçet's disease: an MHC-I-opathy?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 104, 6.	0.8	0
114	FRI0479-Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 611.3-612.	0.9	3
115	AB0433-Disease Characteristics, Survival Analysis and Mortality in A Single Centre Cohort of 240 Patients with Antiphospholipid Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1055.2-1055.	0.9	0
116	A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2208-2211.	0.9	59
117	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1133-1138.	0.9	186
118	FRI0502-Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 620.1-620.	0.9	2
119	Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 296-303.	3.3	33
120	Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet's disease. <i>Genes and Immunity</i> , 2016, 17, 396-399.	4.1	15
121	AB0896-Cogan Syndrome: Differential Response To Biologic Agents and Role of PET-CT in The Increased Diagnosis of Aortitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1208.3-1209.	0.9	0
122	SAT0295-Autoimmune Hemolytic Anemia and Thrombocytopenia in A Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey: Clinical Associations and Effect on Disease Damage and Survival. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 775.1-775.	0.9	0
123	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-Î± Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. <i>Journal of Rheumatology</i> , 2016, 43, 524-529.	2.0	67
124	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. <i>Nature Genetics</i> , 2016, 48, 67-73.	21.4	513
125	Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. <i>Clinical Rheumatology</i> , 2016, 35, 2495-2499.	2.2	7
126	Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1051-1056.	0.9	83

#	ARTICLE	IF	CITATIONS
127	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. <i>Lupus</i> , 2016, 25, 177-184.	1.6	47
128	SAT0343â€¦Utility of Vascular Findings by PET/CT Scan in The Diagnosis and Activity Assessment of Takayasu Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 791.2-791.	0.9	0
129	Cost of Familial Mediterranean Fever (Fmf) Disease In Turkey. <i>Value in Health</i> , 2015, 18, A666.	0.3	3
130	AB0633â€¦A Very High Prevalance of Avascular Necrosis in Turkish Patients with Granulomatosis with Polyangiitis (Wegener's): Preliminary Results from a Single Centre: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1110.3-1111.	0.9	0
131	Generation of integration-free induced pluripotent stem cells from a patient with Familial Mediterranean Fever (FMF). <i>Stem Cell Research</i> , 2015, 15, 694-696.	0.7	14
132	Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. <i>Arthritis Research and Therapy</i> , 2015, 17, 243.	3.5	83
133	THU0561â€¦Salivary IL-1 Alpha and IL-1 Beta Levels Associated with Oral Mucosal Disease Activity in Behcet's Disease: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 403.3-404.	0.9	0
134	FRI0279â€¦High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort:. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 525.3-526.	0.9	0
135	AB1118â€¦Validity and Reliability of Medication Adherence Scale in FMF (Adult Version). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1274.3-1275.	0.9	0
136	Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	0
137	Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-18.	1.3	11
138	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	7.1	139
139	Reply to Stoimenis et al. <i>European Journal of Human Genetics</i> , 2015, 23, 1280-1280.	2.8	0
140	Pathogenesis of Behçet's disease: autoinflammatory features and beyond. <i>Seminars in Immunopathology</i> , 2015, 37, 413-418.	6.1	107
141	Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. <i>Rheumatology International</i> , 2015, 35, 1473-1478.	3.0	12
142	MATHEMATICAL MODELING OF BEHÇET'S DISEASE: A DYNAMICAL SYSTEMS APPROACH. <i>Journal of Biological Systems</i> , 2015, 23, 231-257.	1.4	0
143	'MHC-I-opathy'â€”unified concept for spondyloarthritis and Behçet disease. <i>Nature Reviews Rheumatology</i> , 2015, 11, 731-740.	8.0	183
144	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2436-2441.	2.0	18

#	ARTICLE	IF	CITATIONS
145	Prenatal diagnosis and postnatal outcome of persistent right ductus arteriosus: a report of three cases. <i>Journal of Medical Ultrasonics</i> (2001), 2015, 42, 571-574.	1.3	2
146	The rate and significance of type 1/type 2 serum amyloid A protein gene polymorphisms in patients with ankylosing spondylitis and amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 207-208.	3.0	2
147	FRI0245â€¦Lung Damage in ANCA Associated Vasculitis Assessed by Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 513.2-513.	0.9	0
148	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2465-2469.	2.0	33
149	Identification of possible pathogenic pathways in Behçet's disease using genome-wide association study data from two different populations. <i>European Journal of Human Genetics</i> , 2015, 23, 678-687.	2.8	33
150	Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2015, 253, 457-465.	1.9	22
151	Natural killer cells dominate a Th-1 polarized response in Behçet's disease patients with uveitis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S24-9.	0.8	11
152	FRI0442â€¦Acute Phase Reactants and their Correlation with Clinical Activity in Behcet's Disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 547.1-547.	0.9	0
153	Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8867-8872.	7.1	123
154	Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1414-1418.	1.5	19
155	Genetics of Behçet's disease. <i>Current Opinion in Rheumatology</i> , 2014, 26, 56-63.	4.3	70
156	Recovery from hypoxia and hypercapnic hypoxia: Impacts on the transcription of key antioxidants in the shrimp <i>Litopenaeus vannamei</i> . <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2014, 170, 43-49.	1.6	16
157	Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus from a Single Center. <i>Journal of Rheumatology</i> , 2014, 41, 1304-1310.	2.0	75
158	MEFV gene variations in patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2014, 24, 93-96.	1.8	8
159	FMF50: a score for assessing outcome in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 897-901.	0.9	57
160	Increased IL-23 receptor, TNF-Î± and IL-6 expression in individuals with the IL23Râ€“IL12RB2 locus polymorphism. <i>Immunology Letters</i> , 2014, 160, 96-98.	2.5	15
161	AB0595â€¦Favourable Renal Outcome in AAV Nephritis: A CASE Series Reported from A Tertiary Referral Center. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1002.1-1002.	0.9	0
162	THU0360â€¦Small Bowel Mucosal Findings in Familial Mediterranean Fever. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 307.1-307.	0.9	0

#	ARTICLE	IF	CITATIONS
163	OP0119â€œ...Patient Journey and Treatment Route to Use of First Biologic in Rare Autoinflammatory Diseases: an International Retrospective Chart Review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 106.1-106.	0.9	0
164	Treatment of familial Mediterranean fever: colchicine and beyond. <i>Israel Medical Association Journal</i> , 2014, 16, 281-4.	0.1	17
165	Expression of regulatory receptors on T Cells and their cytokine production in Behçet's disease. <i>Arthritis Research and Therapy</i> , 2013, 15, R15.	3.5	31
166	Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. <i>Nature Genetics</i> , 2013, 45, 202-207.	21.4	483
167	Behçet's disease: immunological relevance with arthritis of ankylosing spondylitis. <i>Rheumatology International</i> , 2013, 33, 733-741.	3.0	18
168	MEFV gene variations in patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	0
169	Ankylosing Spondylitis Health Care Costs And Associated Disease Activity Scores In Turkey. <i>Value in Health</i> , 2013, 16, A222.	0.3	0
170	Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease. <i>Journal of Neuroimmunology</i> , 2013, 263, 139-144.	2.3	17
171	A novel TNFRSF1 gene mutation in a Turkish family: a report of three cases. <i>Clinical Rheumatology</i> , 2013, 32, 83-85.	2.2	2
172	Targeted resequencing implicates the familial Mediterranean fever gene <i>MEFV</i> and the toll-like receptor 4 gene <i>TLR4</i> in Behçet disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8134-8139.	7.1	140
173	Comparison of ultraviolet B-induced cutaneous inflammation and skin pathergy test in Behçet's disease. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 205-211.	0.3	0
174	FRIO210â€œ...Poor immunization with hepatitis B vaccination in patients with granulomatosis with polyangiitis (wegener's) and more favorable antibody response in females. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 385.1-385.	0.9	0
175	THU0203â€œ...Cross-sectional assessment of damage in takayasu arteritis with a validated tool. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 224.1-224.	0.9	1
176	Association of the MEFV Gene Variations With Inflammatory Bowel Disease in Turkey. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, e23-e27.	2.2	35
177	Interleukin-1 ² -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 563-566.	0.9	212
178	PMS37 Productivity Loss of Ankylosing Spondylitis Patients in Turkey Due to Sick Leave. <i>Value in Health</i> , 2012, 15, A40.	0.3	0
179	HLA-B*51 and Behçet Disease. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 37-43.	1.8	86
180	Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. <i>Rheumatology International</i> , 2012, 32, 3277-3279.	3.0	68

#	ARTICLE	IF	CITATIONS
181	Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. <i>Rheumatology International</i> , 2012, 32, 79-83.	3.0	58
182	Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2012, 32, 177-182.	3.0	68
183	Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. <i>Clinical Rheumatology</i> , 2012, 31, 325-328.	2.2	13
184	The regulation of MEFV expression and its role in health and familial Mediterranean fever. <i>Genes and Immunity</i> , 2011, 12, 497-503.	4.1	37
185	Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-BehÄŒet's disease. <i>Journal of Neuroimmunology</i> , 2011, 239, 91-97.	2.3	25
186	Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. <i>Rheumatology International</i> , 2011, 31, 183-189.	3.0	50
187	TNF-alpha antagonist therapy modify the tuberculin skin test response. <i>Rheumatology International</i> , 2011, 31, 1147-1151.	3.0	12
188	Familial Mediterranean Fever and Seronegative Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 388-394.	4.7	39
189	Comparison of perinatal and maternal outcomes of severe preeclampsia, eclampsia, and HELLP syndrome. <i>Journal of the Turkish German Gynecology Association</i> , 2011, 12, 90-96.	0.6	20
190	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2095-2102.	0.9	182
191	Genome-wide association studies in BehÄŒet's disease: expectations and promises. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S3-5.	0.8	10
192	Recurrent anterior uveitis in Henoch Schonleinâ€™s vasculitis. <i>Rheumatology International</i> , 2010, 30, 1377-1379.	3.0	6
193	Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. <i>Rheumatology International</i> , 2010, 30, 1459-1463.	3.0	31
194	Comparison of argon laser photocoagulation-induced cutaneous inflammation and skin pathergy test in BehÄŒetâ€™s disease. <i>Clinical Rheumatology</i> , 2010, 29, 59-63.	2.2	3
195	Comment on the article by Durmus et al. â€œClinical significance of MEFV mutations in ankylosing spondylitisâ€. <i>Joint Bone Spine</i> , 2010, 77, 281.	1.6	6
196	Association of familial Mediterranean feverâ€™related <i>MEFV</i> variations with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3232-3236.	6.7	57
197	Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with BehÄŒet's disease. <i>Nature Genetics</i> , 2010, 42, 698-702.	21.4	595
198	A novel TNFRSF1 gene mutation in a turkish family: report of three cases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A31-A31.	0.9	0

#	ARTICLE	IF	CITATIONS
199	Predicting Important Residues and Interaction Pathways in Proteins Using Gaussian Network Model: Binding and Stability of HLA Proteins. <i>PLoS Computational Biology</i> , 2010, 6, e1000845.	3.2	28
200	Correction: Predictors of damage and survival in patients with Wegener's granulomatosis: Analysis of 50 patients.. <i>Journal of Rheumatology</i> , 2010, 37, 1551.2-1551.	2.0	0
201	The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 61-64.	0.9	508
202	HSP 60 expression in recurrent oral ulcerations of Behçet's disease. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 110, 196-200.	1.4	29
203	Predictors of Damage and Survival in Patients with Wegener's Granulomatosis: Analysis of 50 Patients. <i>Journal of Rheumatology</i> , 2010, 37, 374-378.	2.0	31
204	Genetics of Behçet's Disease. , 2010, , 265-276.		4
205	Low-dose natural human interferon-Î± lozenges in the treatment of Behçet's syndrome. <i>Rheumatology</i> , 2009, 48, 1388-1391.	1.9	20
206	Rosai's Dorfman disease with factor XII deficiency. <i>Clinical Rheumatology</i> , 2009, 28, 733-736.	2.2	4
207	No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behçet's disease. <i>Clinical Rheumatology</i> , 2009, 28, 1385-1388.	2.2	17
208	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. <i>Rheumatology International</i> , 2009, 29, 365-370.	3.0	8
209	Adult-onset still's disease. <i>International Journal of Clinical Practice</i> , 2009, 63, 1050-1055.	1.7	88
210	Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 226-231.	3.0	17
211	Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1528-1534.	0.9	166
212	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. <i>Rheumatology International</i> , 2008, 28, 959-964.	3.0	3
213	Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet Uveitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 1169-1177.	1.9	84
214	Faible fréquence d'HLA-B27 chez des patients atteints de spondylarthrite ankylosante en Turquie. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2008, 75, 433-437.	0.0	1
215	Reevaluation of heterogeneity in HLA-B*510101 associated with Behçet's disease. <i>Tissue Antigens</i> , 2008, 72, 347-353.	1.0	23
216	Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. <i>Joint Bone Spine</i> , 2008, 75, 299-302.	1.6	50

#	ARTICLE	IF	CITATIONS
217	EULAR recommendations for the management of Behcet disease. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1656-1662.	0.9	624
218	Prenatal Diagnosis of Bilateral Ventriculocoronary Fistulas With Hypoplasia of the Left Ventricle. <i>Journal of Ultrasound in Medicine</i> , 2008, 27, 1111-1116.	1.7	3
219	Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. <i>Rheumatology</i> , 2007, 46, 736-741.	1.9	292
220	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 133-140.	3.0	35
221	Standard and Novel Therapeutic Approaches to Behçet's Disease. <i>Drugs</i> , 2007, 67, 2013-2022.	10.9	35
222	Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation. <i>Arthritis and Rheumatism</i> , 2007, 56, 345-350.	6.7	21
223	Pro-inflammatory cellular immune response in Behçet's disease. <i>Rheumatology International</i> , 2007, 27, 1113-1118.	3.0	54
224	Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Behçet's Disease in Turkey. <i>Japanese Journal of Ophthalmology</i> , 2007, 51, 431-436.	1.9	53
225	Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2007, 26, 1913-1915.	2.2	27
226	Distribution of Common CARD15 Variants in Patients with Sporadic Crohn's Disease: Cases from Turkey. <i>Digestive Diseases and Sciences</i> , 2006, 51, 706-710.	2.3	18
227	Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association?. <i>Journal of Neurology</i> , 2006, 253, 928-934.	3.6	53
228	Familial Mediterranean Fever (FMF) in Turkey. <i>Medicine (United States)</i> , 2005, 84, 1-11.	1.0	651
229	Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement. <i>International Journal of Clinical Practice</i> , 2005, 59, 777-781.	1.7	38
230	Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. <i>Arthritis and Rheumatism</i> , 2005, 52, 1836-1842.	6.7	100
231	Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: An open-label trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2478-2484.	6.7	289
232	Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. <i>Rheumatology International</i> , 2005, 25, 211-214.	3.0	28
233	A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. <i>Rheumatology International</i> , 2005, 25, 442-446.	3.0	41
234	Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. <i>Rheumatology International</i> , 2005, 26, 16-20.	3.0	6

#	ARTICLE	IF	CITATIONS
235	Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. <i>Clinical Rheumatology</i> , 2005, 24, 673-676.	2.2	38
236	Behçet's Disease as an Autoinflammatory Disorder. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 81-83.	3.1	210
237	Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease. <i>Rheumatology</i> , 2005, 44, 614-617.	1.9	47
238	Perinatal Outcomes of Twin Pregnancies Discordant for Major Fetal Anomalies. <i>Fetal Diagnosis and Therapy</i> , 2005, 20, 244-248.	1.4	44
239	Perinatal Outcomes in Severe Preeclampsia-Eclampsia with and without HELLP Syndrome. <i>Gynecologic and Obstetric Investigation</i> , 2005, 59, 113-118.	1.6	62
240	Pulmonary Complications of Behçet's Disease. <i>Lung Biology in Health and Disease</i> , 2005, , 377-396.	0.1	0
241	Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behçet's Disease. <i>Annals of Pharmacotherapy</i> , 2004, 38, 808-811.	1.9	32
242	An Unusual Overdose of Leflunomide in a Patient with Rheumatoid Arthritis. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1320-1321.	1.9	5
243	Expression of KIR and C-type lectin receptors in Behçet's disease. <i>British Journal of Rheumatology</i> , 2004, 43, 423-427.	2.3	29
244	Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. <i>International Journal of Clinical Practice</i> , 2004, 58, 1003-1007.	1.7	30
245	Genetic heterogeneity in familial Mediterranean fever: Comment on the article by Cazeneuve et al. <i>Arthritis and Rheumatism</i> , 2004, 50, 1355-1355.	6.7	0
246	Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 3934-3940.	6.7	325
247	Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. <i>Lupus</i> , 2004, 13, 274-278.	1.6	90
248	Immunology and functional genomics of Behçet's disease. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 1903-1922.	5.4	117
249	Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener's granulomatosis. <i>Clinical Rheumatology</i> , 2003, 22, 333-335.	2.2	19
250	Prevalence of Behçet's disease in Istanbul, Turkey. <i>International Journal of Dermatology</i> , 2003, 42, 803-806.	1.0	310
251	Colchicine-Induced Myopathy in a Teenager with Familial Mediterranean Fever. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1821-1824.	1.9	11
252	Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease. <i>British Journal of Rheumatology</i> , 2003, 42, 860-864.	2.3	87

#	ARTICLE	IF	CITATIONS
253	Immunosuppressive therapy in lupus nephritis: The EuroLupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. <i>Arthritis and Rheumatism</i> , 2002, 46, 2121-2131.	6.7	849
254	A weak association of HLA-B*2702 with Behçet's disease. <i>Genes and Immunity</i> , 2002, 3, 368-372.	4.1	61
255	Amyopathic Dermatomyositis Associated with Cervical Cancer. <i>Clinical Rheumatology</i> , 2001, 20, 438-440.	2.2	14
256	Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test. <i>Arthritis and Rheumatism</i> , 2001, 44, 239-241.	6.7	86
257	Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22-23. <i>Arthritis and Rheumatism</i> , 2001, 44, 2693-2696.	6.7	63
258	Rare diseases bullet 12: Pulmonary manifestations of Behçet's disease. <i>Thorax</i> , 2001, 56, 572-578.	5.6	208
259	Lack of association of HLA-B*51 with a severe disease course in Behçet's disease. <i>British Journal of Rheumatology</i> , 2001, 40, 668-672.	2.3	67
260	Clinical course of ocular Behçet's disease in siblings. <i>Ocular Immunology and Inflammation</i> , 2001, 9, 111-124.	1.8	6
261	Familial aggregation of Behçet's disease in Turkey. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 622-625.	0.9	164
262	Procoagulant mutations and venous thrombosis in Behçet's disease. <i>Rheumatology</i> , 1999, 38, 1298-1299.	1.9	48
263	Organizing pneumonia associated with pulmonary artery aneurysms in Behçet's disease. <i>Rheumatology</i> , 1999, 38, 1285-1289.	1.9	42
264	CT findings of pulmonary artery aneurysms during treatment for Behçet's disease. <i>American Journal of Roentgenology</i> , 1999, 172, 729-733.	2.2	126
265	The Use of Two Different Health Assessment Questionnaires in Turkish Rheumatoid Arthritis Population and Assessment of the Associations with Disability. <i>Clinical Rheumatology</i> , 1999, 18, 33-37.	2.2	12
266	Shared epitope homozygosity' is strongly associated with rheumatoid arthritis in Turkey. Istanbul Rheumatology Study Group. <i>British Journal of Rheumatology</i> , 1998, 37, 1126-1128.	2.3	11
267	HLA-B51 negative monozygotic twins discordant for Behçet's disease. <i>Rheumatology</i> , 1997, 36, 922-923.	1.9	12
268	Peripheral blood T cell expansions in patients with Behçet's disease. <i>Clinical and Experimental Immunology</i> , 1997, 107, 520-527.	2.6	63
269	Primary antiphospholipid syndrome associated with mesenteric inflammatory veno-occlusive disease. <i>Clinical Rheumatology</i> , 1996, 15, 207-210.	2.2	34
270	COAGULATION FACTOR V GENE MUTATION INCREASES THE RISK OF VENOUS THROMBOSIS IN BEHÇET'S DISEASE. <i>Rheumatology</i> , 1996, 35, 1178-1180.	1.9	102

#	ARTICLE	IF	CITATIONS
271	Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus. <i>Lupus</i> , 1996, 5, 120-122.	1.6	17
272	Immunohistology of skin pathergy reaction in Behçet's disease. <i>British Journal of Dermatology</i> , 1995, 132, 901-907.	1.5	121
273	Comparative study of the skin pathergy test with blunt and sharp needles in Behçet's disease: confirmed specificity but decreased sensitivity with sharp needles.. <i>Annals of the Rheumatic Diseases</i> , 1993, 52, 823-825.	0.9	100
274	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.9	0